Richard M. Steingart

10.3k total citations · 1 hit paper
140 papers, 4.9k citations indexed

About

Richard M. Steingart is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Richard M. Steingart has authored 140 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Cardiology and Cardiovascular Medicine, 51 papers in Oncology and 49 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Richard M. Steingart's work include Chemotherapy-induced cardiotoxicity and mitigation (49 papers), Cardiac Imaging and Diagnostics (45 papers) and HER2/EGFR in Cancer Research (26 papers). Richard M. Steingart is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (49 papers), Cardiac Imaging and Diagnostics (45 papers) and HER2/EGFR in Cancer Research (26 papers). Richard M. Steingart collaborates with scholars based in United States, Canada and United Kingdom. Richard M. Steingart's co-authors include Anthony F. Yu, Chau T. Dang, Jennifer E. Liu, Jessica B. Long, Cary P. Gross, Jersey Chen, Arti Hurria, Cynthia Owusu, John Wexler and Clifford A. Hudis and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Experimental Medicine.

In The Last Decade

Richard M. Steingart

131 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sex Differences in the Management of Coronary Artery Disease

1991 731 citations Richard M. Steingart, Stanley Katz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard M. Steingart United States	37	3.1k	1.5k	1.1k	761	737	140	4.9k
Anju Nohria United States	43	4.6k 1.5×	1.7k 1.1×	1.0k 0.9×	913 1.2×	1.4k 1.9×	149	6.8k
Anne Blaes United States	29	1.0k 0.3×	1.7k 1.1×	360 0.3×	506 0.7×	454 0.6×	194	3.6k
Nicholas G. Zaorsky United States	43	709 0.2×	2.5k 1.7×	1.0k 0.9×	876 1.2×	3.1k 4.2×	229	6.7k
Husam Abdel‐Qadir Canada	29	1.5k 0.5×	683 0.5×	413 0.4×	289 0.4×	407 0.6×	124	2.4k
Per Albertsson Sweden	43	3.7k 1.2×	685 0.5×	2.6k 2.3×	2.9k 3.9×	939 1.3×	174	6.9k
Eva Culakova United States	38	1.7k 0.5×	2.8k 1.9×	161 0.1×	755 1.0×	860 1.2×	180	7.0k
Malini Chandra United States	22	1.2k 0.4×	588 0.4×	402 0.4×	652 0.9×	141 0.2×	71	2.8k
Andrew Wragg United Kingdom	28	1.4k 0.4×	420 0.3×	968 0.9×	1.1k 1.5×	348 0.5×	122	4.0k
Harold L. Dauerman United States	34	2.5k 0.8×	432 0.3×	808 0.7×	1.8k 2.3×	732 1.0×	138	4.6k
C S McArdle United Kingdom	45	826 0.3×	4.5k 3.0×	576 0.5×	2.8k 3.7×	1.5k 2.0×	157	7.7k

Countries citing papers authored by Richard M. Steingart

Since Specialization

Citations

This map shows the geographic impact of Richard M. Steingart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard M. Steingart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard M. Steingart more than expected).

Fields of papers citing papers by Richard M. Steingart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard M. Steingart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard M. Steingart. The network helps show where Richard M. Steingart may publish in the future.

Co-authorship network of co-authors of Richard M. Steingart

This figure shows the co-authorship network connecting the top 25 collaborators of Richard M. Steingart. A scholar is included among the top collaborators of Richard M. Steingart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard M. Steingart. Richard M. Steingart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Anthony F., Chau T. Dang, Chaya S. Moskowitz, et al.. (2023). Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-Oncology. 9(1). 13–13. 4 indexed citations

Park, Michael, Robert Park, José Jessurun, et al.. (2023). Survivorship in patients with cardiac metastases defined by cardiac magnetic resonance imaging in relation to lesion hypoperfusion.. Journal of Clinical Oncology. 41(16_suppl). e24070–e24070.

Park, Christine, John D. Grizzard, Gene Kim, et al.. (2023). Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac Masses. JACC. Cardiovascular imaging. 17(2). 128–145.

Salz, Talya, Emily C. Zabor, Peter de Nully Brown, et al.. (2022). Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors. Acta Oncologica. 61(9). 1064–1068. 4 indexed citations

Shamseddine, A., Zachary Moore, Melody Di Bona, et al.. (2022). Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies. The Journal of Experimental Medicine. 220(3). 15 indexed citations

Plodkowski, Andrew J., Dipti Gupta, Yulia Lakhman, et al.. (2020). Diagnostic utility and clinical implication of late gadolinium enhancement cardiac magnetic resonance for detection of catheter associated right atrial thrombus. Clinical Imaging. 62. 17–22. 4 indexed citations

Al‐Sadawi, Mohammed, Sujata Patil, Jennifer E. Liu, et al.. (2020). Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer. JAMA Oncology. 6(12). 1971–1971. 20 indexed citations

Yu, Anthony F., Andrea Knežević, Chaya S. Moskowitz, et al.. (2018). PROSPECTIVE EVALUATION OF CIRCULATING BIOMARKERS AS PREDICTORS OF CARDIOTOXICITY IN PATIENTS WITH HER2-POSITIVE BREAST CANCER RECEIVING ANTHRACYCLINES AND TRASTUZUMAB. Journal of the American College of Cardiology. 71(11). A691–A691. 1 indexed citations

Landau, Heather, Elyn Riedel, Anthony F. Yu, et al.. (2017). Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. Journal of the American Society of Echocardiography. 31(1). 64–70. 39 indexed citations

10.

Yu, Anthony F., Jasmeet Singh, Rui Wang, et al.. (2017). Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. The Oncologist. 22(6). 642–647. 27 indexed citations

11.

Yu, Anthony F., Carlos Manrique, Jennifer E. Liu, et al.. (2016). Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. The Oncologist. 21(4). 418–424. 38 indexed citations

12.

Yu, Anthony F., Anne Eaton, Howard T. Thaler, et al.. (2014). Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Research and Treatment. 149(2). 489–495. 68 indexed citations

13.

Morris, Patrick G., Neil M. Iyengar, Sujata Patil, et al.. (2013). Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 119(22). 3943–3951. 15 indexed citations

14.

Yu, Anthony F., Carlos Manrique, Howard T. Thaler, et al.. (2013). Abstract 9317: Impact of Trastuzumab-Induced Cardiotoxicity and Subsequent Trastuzumab Interruption on Breast Cancer Outcome. Circulation. 128(suppl_22). 2 indexed citations

15.

Feldman, Darren R., Wendy Schaffer, & Richard M. Steingart. (2012). Late Cardiovascular Toxicity Following Chemotherapy for Germ Cell Tumors. Journal of the National Comprehensive Cancer Network. 10(4). 537–544. 48 indexed citations

16.

Krebs, Paul, Elliot J. Coups, Marc B. Feinstein, et al.. (2011). Health behaviors of early-stage non-small cell lung cancer survivors. Journal of Cancer Survivorship. 6(1). 37–44. 23 indexed citations

17.

Dang, Chau T., Nancy U. Lin, Beverly Moy, et al.. (2010). Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. Journal of Clinical Oncology. 28(18). 2982–2988. 36 indexed citations

18.

French, J., Henry A. Feldman, Susan F. Assmann, et al.. (2003). Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. American Heart Journal. 146(5). 804–810. 33 indexed citations

19.

Pepine, Carl J., Thomas Andrews, Sandra Forman, et al.. (1997). Relation Between Clinical, Angiographic and Ischemic Findings at Baseline and Ischemia-Related Adverse Outcomes at 1 Year in the Asymptomatic Cardiac Ischemia Pilot Study fn1fn1This study was funded by the National Heart, Lung, and Blood Institute, Cardiac Diseases Branch, Division of Heart and Vascular Diseases, National Institutes of Health, Bethesda, Maryland, by Research Contracts HV-90-07, HV90-08, HV-91-05 to HV-91-14. Study medications and placebo were donated by Zeneca Pharmaceuticals Group, Wilmington, Delaware; Marion-Merrell Dow, Kansas City, Missouri; and Pfizer, New York, New York. Support for electrocardiographic data collection was provided in part by Applied Cardiac Systems, Laguna Hills, California; Marquette Electronics, Milwaukee, Wisconsin; Mortara Instrument, Milwaukee, Wisconsin; and Quinton Instruments, Seattle, Washington. Some centers had partial support from grants from the General Clinical Research Center, National Institutes of Health.. Journal of the American College of Cardiology. 29(7). 1483–1489. 26 indexed citations

20.

Steingart, Richard M., et al.. (1989). Effects of intravenous metoprolol on global and regional left ventricular function after coronary arterial reperfusion in acute myocardial infarction. The American Journal of Cardiology. 63(12). 767–771. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact